NCT02273349

Lung Volume Reduction Coils for Emphysema in Alpha-1 Antitrypsin Deficiency

Evaluation of the PneumRx, Inc. Lung Volume Reduction Coil for the Treatment of Emphysema in Alpha-1 Antitrypsin Deficient Patients

• Status: Withdrawn
• Phase: N/A
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: University Hospital, Saarland · Academic / Other
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

The objective of this study is to evaluate the safety and effectiveness of the RePneu Lung Volume Reduction Coil (LVRC) in patients with Alpha-1-Antitrypsin deficiency (AATD) caused emphysema. The hypothesis is that emphysema in AATD patients shows similar tissue destruction profile was well as symptoms and thus will respond favorably to LVRC treatment, demonstrating improvement in lung function, exercise capacity, and quality of life relative to their baseline status.

Conditions

• Alpha-1-Antitrypsin Deficiency
• Chronic Obstructive Lung Disease
• Emphysema

Interventions

Type	Name	Description
DEVICE	Lung Volume Reduction Coil (PneumrX Inc.)	Endoscopic Lung Volume Reduction

Timeline

• Start date: 2014-10-01
• Primary completion: 2015-08-01
• Completion: 2015-10-01
• First posted: 2014-10-23
• Last updated: 2017-05-02

Locations

2 sites across 2 countries: Denmark, Germany